Who are Fusilev's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PEMETREXED DIPOTASSIUM, Fusilev, Alimta, Wellcovorin, FOLFOX4s, Leucovorin (or Levoleucovorin).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levoleucovorin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Fusilev — Competitive Intelligence Brief

Fusilev (levoleucovorin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Folate Analog. Area: Oncology.

marketed Folate Analog Oncology Live · refreshed every 30 min

Target snapshot

Fusilev (levoleucovorin) — Acrotech Biopharma. Fusilev works by bypassing the enzyme dihydrofolate reductase, allowing normal cell growth and DNA synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fusilev TARGET	levoleucovorin	Acrotech Biopharma	marketed	Folate Analog		2008-01-01
PEMETREXED DIPOTASSIUM	PEMETREXED DIPOTASSIUM		marketed	Folate Analog Metabolic Inhibitor [EPC]		2024-01-01
Fusilev	Levofolinic acid	Spectrum Pharms	marketed	Folate Analog		2008-01-01
Alimta	pemetrexed	Actavis	marketed	Folate Analog Metabolic Inhibitor	Folate receptor alpha	2004-01-01
Wellcovorin	leucovorin	Pfizer Japan Inc	marketed	Folate Analog	Dihydrofolate reductase	1952-01-01
FOLFOX4s	FOLFOX4s	UNICANCER	phase 3	Chemotherapy regimen (combination of antimetabolite, folate analog, and platinum agent)	Thymidylate synthase (5-FU), DNA (oxaliplatin)
Leucovorin (or Levoleucovorin)	Leucovorin (or Levoleucovorin)	Merck Sharp & Dohme LLC	phase 3	Folate analog / Chemotherapy adjuvant	Dihydrofolate reductase (indirect); thymidylate synthase (potentiation)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-10-28 — Alimta · 9604990 · Compound · US
2036-02-19 — Alimta · 12115164 · Method of Use · US
2036-02-19 — Alimta · 11793813 · Formulation · US
2039-03-25 — Fusilev · 11541012 · US

Sponsor landscape (Folate Analog class)

Acrotech Biopharma · 1 drug in this class
Pfizer Japan Inc · 1 drug in this class
Spectrum Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fusilev — Competitive Intelligence Brief. https://druglandscape.com/ci/levoleucovorin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab